Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is actively engaging in discussions with regulators and submitting additional data to align upon a potential NDA pathway for early Alzheimer's disease, while maintaining active dialogue to address CHMP feedback in Europe. Additionally, the company is broadening regulatory engagement in other indications, reinforcing its multi-indication potential. These developments support the company's longer-term optionality and could lead to a stronger submission package and potential regulatory approvals, making it a key near-term inflection point for the company. While the recent withdrawal from the EU may appear negative, it is a disciplined decision to avoid a likely rejection and preserve optionality and credibility with regulators. The company's focus on precision medicine and the correlation between brain volume preservation and clinical outcomes could make blarcamesine a promising potential treatment for Alzheimer's disease and other CNS disorders.

Bears say

Anavex Life Sciences is facing timing uncertainty and decreased probability of success for their drug candidates in major markets like the US and EU. This will not only impact potential revenues and future growth, but also raises concerns about the effectiveness of their current development strategy. While management remains focused on advancing their drug, these factors contribute to a negative outlook on the stock.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.